News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Rubin_David_4_web.jpg)
Cumulative inflammatory burden predicts cancer risk in ulcerative colitis
- Author:
- Bruce Jancin
Second study validates cumulative microscopic inflammation score as independent predictor of colorectal neoplasia.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/telemed_docdiscussingmeds_web.jpg)
Telerheumatology will thrive post pandemic
- Author:
- Bruce Jancin
Physician-to-physician teleconsults and remote patient monitoring are predicted to be growth areas.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Troum_Orrin_M_CA21_web.jpg)
Point-Counterpoint: The future of rheumatology is sub-subspecialization
- Author:
- Bruce Jancin
The rheumatology workforce shortage is here and growing.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/March-2018/Ruderman_Eric_IL2_web.jpg)
Checkpoint inhibitor–induced rheumatic complications often arise late
- Author:
- Bruce Jancin
Rheumatologic adverse events associated with immune checkpoint inhibitors can happen later in the course of treatment but also can continue after...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/February-2018/Troum_Orrin_M_CA_2_web.jpg)
Evidence grows for food as RA treatment
- Author:
- Bruce Jancin
An enhanced anti-inflammatory diet shows promise for symptom reduction.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Ogdie Beatty_Alexis_PA_web.jpg)
To improve psoriatic arthritis outcomes, address common comorbidities
- Author:
- Bruce Jancin
Depression and obesity are associated with poor treatment response in PsA.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Wells_Alvin_F_WI_3_web.jpg)
Novel lupus therapies take center stage
- Author:
- Bruce Jancin
Speakers at the 2021 Rheumatology Winter Clinical Symposium spotlighted new drug approvals and new mechanisms of action in SLE, as well as...
News
![Psoriasis on elbow](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/August-2018/Psoriasis_NPF_07_web.jpg)
Recent psoriasis pathophysiology insights carry treatment implications
- Author:
- Bruce Jancin
“The primary problem in psoriasis is not so much the inflammatory activity, but the ability to turn off the activity.”
News
![](https://qa00.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
RA experts highlight key developments over the past year
- Author:
- Bruce Jancin
Highlights include lymphoma risk reduction with biologics, low-dose corticosteroid risk, stratifying VTE risk, treat-to-target strategies and...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Ruderman_Eric_M_IL_web.jpg)
Rise of JAK inhibitors highlights axial spondyloarthritis year in review
- Author:
- Bruce Jancin
Panelists at the 2021 Rheumatology Winter Clinical Symposium discussed the impact JAK inhibitors will have on the management of patients with...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/osteoporosis_notepad_web.jpg)
Romosozumab may not increase cardiovascular risk after all
- Author:
- Bruce Jancin
Could a cardioprotective effect of bisphosphonates in a pivotal clinical trial of romosozumab explain why the biologic was given a black-box...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Postolova_Anna_CALIFORNIA_web.jpg)
Consider home subcutaneous immune globulin for refractory dermatomyositis
- Author:
- Bruce Jancin
Patients prefer home subQ over IVIg, citing greater feeling of autonomy.
News
Molecular insights suggest novel therapies for hidradenitis suppurativa
- Author:
- Bruce Jancin
Many key molecular pathways involved in HS pathogenesis can be targeted by commercially available agents having other indications.
News
Anybody for a nanobody? Novel psoriasis therapy impresses in phase 2b
- Author:
- Bruce Jancin
Sonelokinab, which inhibits interleukin-17A/F, provided exceptionally rapid clinical improvement.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Kirkwood_John_Pittsburgh_web.jpg)
Neoadjuvant immunotherapy shows promise in stage III melanoma
- Author:
- Bruce Jancin
There is both preclinical and clinical evidence that neoadjuvant therapy may offer a survival advantage over adjuvant therapy.